Epstein-Barr virus Latent Membrane Protein 1-derived peptide–HLA class I complexes (LMP1-HLA I complexes)

Epstein-Barr virus (EBV) Latent Membrane Protein 1 (LMP1)-derived peptide–HLA class I complexes are molecular assemblies presented on the surface of cells latently infected with EBV. These complexes consist of short, processed peptides from the LMP1 oncoprotein—such as YLLEMLWRL or YLQQNWWTL—bound within the groove of Human Leukocyte Antigen (HLA) class I molecules, most commonly HLA-A*02:01 (1.2.2, 1.5.5). LMP1 is a critical driver of EBV-mediated oncogenesis, functioning as a constitutive mimic of the CD40 receptor to activate pro-survival and proliferative pathways in B cells and epithelial cells (1.1.1, 1.3.2). Because LMP1 is expressed in several EBV-associated malignancies, including nasopharyngeal carcinoma, Hodgkin lymphoma, and NK/T-cell lymphomas, these peptide-MHC (pMHC) complexes serve as specific targets for cellular immunotherapies (1.3.1, 1.4.1). Therapeutic strategies currently under investigation include T-cell receptor-engineered T cells (TCR-T) like YT-E001, TCR-like antibodies such as L1, and epitope-based vaccines designed to elicit a robust cytotoxic T lymphocyte response (2.2.1, 2.3.2). However, the clinical efficacy of targeting these complexes is often limited by the low density of LMP1 presentation and the virus's ability to downregulate HLA expression to evade immune surveillance (1.4.2, 2.3.3).

Other names

EBV LMP1 pMHCLMP1 peptide-MHC class I complexesEBV LMP1-HLA complexesYLLEMLWRL-HLA-A*02:01 complexYLQQNWWTL-HLA-A*02:01 complexTLLVDLLWL-HLA-A*02:01 complexIIIILIIFI-HLA-A*02:06 complexIALYLQQNW-HLA-A*24:02 complex

T-cell receptor-mediated cytotoxicity, Antibody-dependent cellular cytotoxicity, Vaccine-induced immune activation